Tag Archives: Merck
Notes and Analysis from Merck’s Investor Day
On June 20, Merck held an investor day, its first in five years, to highlight its goals and objectives and provide a broad perspective on its five-year performance outlook. Although its blockbuster cancer treatment, KEYTRUDA (pembrolizumab), has been a spectacular … Continue reading
Posted in Health Care, MRK
Tagged Merck, Pharmaceutical industry
Comments Off on Notes and Analysis from Merck’s Investor Day